



Biomarkers and Precision Medicine in Upper Gastrointestinal Malignancies

Guest Editor:

Prof. Dr. Morten Ladekarl

Department of Oncology, Aalborg
University Hospital, Hobrovej 18-
22, 9000 Aalborg, Denmark

Deadline for manuscript
submissions:

closed (30 April 2025)

Message from the Guest Editor

Dear Colleagues,

The current treatment of patients with upper gastrointestinal cancers is centred around chemotherapy and surgery, with a limited number of patients being candidates for immunotherapy or molecularly targeted treatment based on biomarker selection. The poor efficacy of treatment, late diagnoses, and the aggressive behavior of most cases contribute to the high mortality of these diseases.

To improve results, one major approach pursues the stratification of patients, according to the molecular characteristics for predicting treatment responses or resistance. Other strategies focus on novel biomarkers for early diagnosis, the detection of progression or relapse, or prognosis.

We invite researchers to publish studies within this topic in upper gastrointestinal malignancies, including esophageal-gastric, pancreatic, duodenal/small bowel, and hepatic-biliary cancers.

I look forward to receiving your contributions.

Prof. Dr. Morten Ladekarl
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada

2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

Message from the Editor-in-Chief

I am honored and enthusiastic to serve as Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases.**

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Current Oncology Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/currenconcol
currentoncology@mdpi.com
[X@CurrentOncology](https://twitter.com/CurrentOncology)